DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Kindler HL, Campbell NP, Wroblewski K et al.
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
J Clin Oncol 2011;
29 abstr 10009
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.